Philip Young
Chief Executive Officer at LOBE SCIENCES LTD.
Net worth: 8 288 $ as of 31/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Baxter Phillips | M | 48 |
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 10 years |
| Frederick Sancilio | M | 74 | - | |
| Sandra Dosdall | F | 55 | - | |
| Michael Petter | M | - | 3 years | |
| Maghsoud Dariani | M | - | 4 years | |
| Mathew Lee | M | 40 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kevin P. Tully | M | 70 | 11 years | |
| Kelley A. Wendt | F | 49 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 7 years |
| Jonathan Gilbert | M | 52 | 3 years | |
| Timothy Ryan | M | 63 | 3 years | |
| Leighton Bocking | M | 41 | 2 years | |
| David O'Flynn | M | - | - | |
| John Price | M | 54 | 2 years | |
| Thomas Baird | M | - | 1 years | |
| Elliot M. Maza | M | 68 | 1 years | |
| Emiliano Aloi | M | 50 | 1 years | |
| Sandra Morales | M | - |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | - |
| Charles Casamento | M | 78 | 3 years | |
| Kenneth E. Puzder | M | 58 | 1 years | |
| Vladislav Yampolsky | M | 47 | 1 years | |
| Steven Allen Schwartz | M | 80 | - | |
| John M. Barberich | M | 66 | 3 years | |
| Kevin James Esval | M | 60 | 1 years | |
| Andrew L. Johnson | M | 38 | 2 years | |
| Nathan Berman | M | 36 | - | |
| David E. Bosher | M | 70 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 2 years |
| Jeffrey Thompson | M | 60 | 1 years | |
| Karen J. Harder | F | 66 |
Gantech International, Inc.
| - |
| William Glennon | M | - |
AGY Therapeutics, Inc.
 AGY Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AGY Therapeutics, Inc. develops new therapies for diseases and disorders. It develops central nervous system therapeutics for the treatments of neurodegenerative diseases, CNS injuries, stroke, and schizophrenia. The company was founded by Robert Swanson and Karoly Nikolich in 1998 and is headquartered in South San Francisco, CA. | - |
| Cynthia J. Ladd | F | 68 |
AGY Therapeutics, Inc.
AGY Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AGY Therapeutics, Inc. develops new therapies for diseases and disorders. It develops central nervous system therapeutics for the treatments of neurodegenerative diseases, CNS injuries, stroke, and schizophrenia. The company was founded by Robert Swanson and Karoly Nikolich in 1998 and is headquartered in South San Francisco, CA. | 2 years |
| Wendy Johnson | F | 72 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 5 years |
| Matthew M. Loar | M | 61 | 2 years | |
| Christopher Barry Wood | M | 78 | - | |
| Brian Zasitko | M | 44 | 3 years | |
| Thomas Keuer | M | 65 | 2 years | |
| Stephen Glover | M | 60 | 4 years | |
| William Young | M | 79 |
AGY Therapeutics, Inc.
AGY Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AGY Therapeutics, Inc. develops new therapies for diseases and disorders. It develops central nervous system therapeutics for the treatments of neurodegenerative diseases, CNS injuries, stroke, and schizophrenia. The company was founded by Robert Swanson and Karoly Nikolich in 1998 and is headquartered in South San Francisco, CA. | - |
| Jeremy Curnock-Cook | M | 74 | 3 years | |
| James R. Erickson | M | 62 | 3 years | |
| Anthony P. Gellert | M | - |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | - |
| Elizabeth Czerepak | F | 58 |
AGY Therapeutics, Inc.
AGY Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AGY Therapeutics, Inc. develops new therapies for diseases and disorders. It develops central nervous system therapeutics for the treatments of neurodegenerative diseases, CNS injuries, stroke, and schizophrenia. The company was founded by Robert Swanson and Karoly Nikolich in 1998 and is headquartered in South San Francisco, CA. | 4 years |
| Anthony Smithyman | M | 74 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 3 years |
| Enda Kenny | M | - | 2 years | |
| Hanns Mohler | M | - |
AGY Therapeutics, Inc.
AGY Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AGY Therapeutics, Inc. develops new therapies for diseases and disorders. It develops central nervous system therapeutics for the treatments of neurodegenerative diseases, CNS injuries, stroke, and schizophrenia. The company was founded by Robert Swanson and Karoly Nikolich in 1998 and is headquartered in South San Francisco, CA. | - |
| Laura Edgerly-Pflug | F | 60 | 7 years | |
| Christian Hansen | M | 58 | - | |
| Krassen Dimitrov | M | - | 1 years | |
| Caroline Ann Williams | M | 70 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | - |
| Kenneth Attie | M | 67 | 3 years | |
| Julian P. Kirk | M | 50 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 2 years |
| Florian Schönharting | M | 55 | - | |
| Bobby Sandage | M | 70 | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 34 | 65.38% |
| Ireland | 11 | 21.15% |
| Canada | 10 | 19.23% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Philip Young
- Personal Network
